retatrutide fda approval status 2025 approval: status, clinical trial results, and when it could be available Retatrutide Promises Big Weight Loss,
Description
When people stop GLP-1 therapy, some microbiome changes reverse, which may contribute to weight regain
The drug makes a patient feel full more quickly and for a longer period of time, reducing overall food consumption, and consequently leading to weight loss
Early research has not found an increased risk of major developmental issues during early pregnancy from GLP-1 exposure
El tratamiento de la DM tiene como objetivos asegurar al paciente una buena calidad de vida, disminuir el riesgo de complicaciones especficas (retinopata, nefropata, neuropata) y de eventos cardiovasculares (CV) que son su principal causa de mortalidad
Picchietti, D
